The purpose of this guidance is to provide recommendations to sponsors developing medical products on the approach for developing a Race and Ethnicity Diversity Plan (referred to as the “Plan”) to enroll adequate numbers of participants in clinical trials from underrepresented racial and ethnic populations in the United States.

The FDA released a Federal Regulatory Notice on the topic of improving the diversity considerations for clinical trials on April 14, 2022. Subsequent releases have since been published by the FDA including an infographic and brochure.
Clinical Trials Infographic (see attached document)

Clinical Trials Brochure (see attached document)

Please see the FDA announcement on these new clinical trial diversity guidelines here and further information here.